Benchmark Reiterates Buy on Bio-Techne, Maintains $120 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Robert Wasserman has reiterated a 'Buy' rating on Bio-Techne (NASDAQ:TECH) and maintained a price target of $120.
August 18, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst has reiterated a 'Buy' rating on Bio-Techne and maintained a price target of $120.
The reiteration of a 'Buy' rating by a Benchmark analyst and the maintenance of a $120 price target indicates a positive outlook for Bio-Techne. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100